Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BECN1 | Q14457 | 13/20 | 0.59 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.53 |
| ▸ | KCNMB4 | Q86W47 | 1/20 | 0.53 |
| ▸ | ALB | P02768 | 1/20 | 0.52 |
| ▸ | INSR | P06213 | 1/20 | 0.51 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.50 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.50 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.50 |
| ▸ | NPR1 | P16066 | 1/20 | 0.49 |
| ▸ | NPR3 | P17342 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8991433 | 0.95 | BECN1 (0.63) | BECN1KCNMA1KCNMB4ALBINSR | |
| SCHEMBL29352842 | 0.91 | BECN1 (0.63) | BECN1KCNMA1KCNMB4ALBINSR | |
| SCHEMBL17236232 | 0.91 | BECN1 (0.70) | BECN1KCNMA1KCNMB4ALBINSR | |
| SCHEMBL14654850 | 0.88 | BECN1 (0.67) | BECN1KCNMA1KCNMB4ALBINSR | |
| SCHEMBL17236230 | 0.87 | BECN1 (0.66) | BECN1KCNMA1KCNMB4ALBINSR | |
| SCHEMBL29470903 | 0.73 | TFPI (0.64) | — | |
| SCHEMBL31437676 | 0.72 | NPY4R (0.60) | — | |
| SCHEMBL16015184 | 0.70 | TFPI (0.61) | — | |
| SCHEMBL12359225 | 0.70 | TFPI (0.61) | — | |
| SCHEMBL13912288 | 0.70 | TFPI (0.61) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102708-B2 | Methods for the synthesis of dicarba bridges in organic compounds | SYNGENE LIMITED (AU) | 2015-08-11 | — | — | US | disclosed |
| US-8188217-B2 | — | — | 2012-05-29 | — | — | US | disclosed |
| US-20100036089-A1 | Methods for the Synthesis of Dicarba Bridges in Organic Compounds | MONASH UNIVERSITY (AU) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036089-A1 | Methods for the Synthesis of Dicarba Bridges in Organic Compounds | DCLRE1A, RNF168, MTCL3 | BECN1 1272/4885KCNMA1 2370/4885KCNMB4 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.